[Secretases as therapeutic targets for the treatment of Alzheimer's disease].
Alzheimer's disease is the most frequent degenerative disorder of the central nervous system. A focus on the familial, monogenetic disease subtypes has put researchers on the trail of the primary pathogenetic agent, the Abeta-peptide. The production of this peptide is being controlled by a number of proteolytic enzymes commonly known as the "secretases". An intensive study of the molecular and cell biological functions of these secretases is undertaken with the aim of generating drugs to cure Alzheimer's disease.
Dejaegere
T
T
de Strooper
B
B
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology*; D053829:Amyloid Precursor Protein Secretases; D016564:Amyloid beta-Protein Precursor / Q000502:physiology*; D016282:Aspartic Acid Endopeptidases; D010450:Endopeptidases / Q000235:genetics / Q000502:physiology*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use
D016564:Amyloid beta-Protein Precursor; D011480:Protease Inhibitors; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human